SCHEMBL3018295

SCHEMBL3018295

CCOC(=O)C1CN2CCN1C(C)=C2C

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.40
KMT2A Q03164 2/20 0.40
LMNA P02545 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
MAPT P10636 4/20 0.38
MEN1 O00255 1/20 0.37
FKBP1A P62942 2/20 0.37
CHRM2 P08172 1/20 0.36
CHRM4 P08173 1/20 0.36
CHRM5 P08912 1/20 0.36
CHRM1 P11229 1/20 0.36
CHRM3 P20309 1/20 0.36
CACNA1A O00555 1/20 0.36
CACNA2D1 P54289 1/20 0.36
CACNB1 Q02641 1/20 0.36
TSHR P16473 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
KDM4E B2RXH2 2/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3016719 0.86 ALDH1A1 (0.38) ALDH1A1KMT2ALMNASMN1; SMN2MAPT
SCHEMBL3019564 0.86 ALDH1A1 (0.38) ALDH1A1KMT2ALMNASMN1; SMN2MAPT
SCHEMBL3009557 0.83 ALDH1A1 (0.37) ALDH1A1KMT2AFKBP1A
SCHEMBL3014714 0.82 CHRM2 (0.37) ALDH1A1LMNASMN1; SMN2MAPTCHRM2
SCHEMBL3013693 0.77 MAPT (0.42) ALDH1A1KMT2ASMN1; SMN2MAPTMEN1
SCHEMBL3003396 0.77 AGTR2 (0.36) ALDH1A1KMT2AMAPTMEN1NPSR1
SCHEMBL3014713 0.76
SCHEMBL3014717 0.75
SCHEMBL3014782 0.73 FKBP1A (0.33) ALDH1A1KMT2AMEN1FKBP1ACHRM2
SCHEMBL3024248 0.73 ALDH1A1 (0.40) ALDH1A1KMT2ALMNASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100204438-A1 METHOD FOR PRODUCING TEDA DERIVATIVES BASF SE (DE) 2010-08-12 US disclosed
EP-2197882-A2 METHOD FOR PRODUCING TEDA DERIVATIVES Basf Se (DE) 2010-06-23 EP disclosed
WO-2009030649-A2 METHOD FOR PRODUCING TEDA DERIVATIVES BASF SE (DE) 2009-03-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204438-A1 METHOD FOR PRODUCING TEDA DERIVATIVES TES, TRRAP, NAAA ALDH1A1 720/4885KMT2A 98/4885LMNA 2940/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.